You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Trophoblast cell surface antigen

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)

Not yet recruiting
  • Resolved Hepatitis B
  • CD20 Positive B-cell Lymphoma
  • (no location specified)
Jul 10, 2022

Malignant Pleural Disease, Mesothelioma, Metastases Trial in United States (iCasp9M28z T cell infusions, cyclophosphamide,

Active, not recruiting
  • Malignant Pleural Disease
  • +4 more
  • iCasp9M28z T cell infusions
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 14, 2022

Influenza, Human Trial in Brisbane (ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine

Not yet recruiting
  • Influenza, Human
  • ARCT-2138
  • +2 more
  • Brisbane, Queensland, Australia
    Nucleus Network Brisbane Clinic
Nov 8, 2023

Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)

Not yet recruiting
  • Triple-negative Breast Cancer
  • A1: SHR-A1811
  • +11 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 19, 2023

Endometrial Cancer Trial (MK-2870, Doxorubicin, Paclitaxel)

Not yet recruiting
  • Endometrial Cancer
  • MK-2870
  • +2 more
  • (no location specified)
Nov 10, 2023

Advanced Cancer, Advanced Solid Tumor, Cancer Trial in Austin, Houston, Fairfax (BIO-106, Pembrolizumab)

Recruiting
  • Advanced Cancer
  • +3 more
  • Austin, Texas
  • +2 more
Jul 15, 2022

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Sacituzumab Govitecan
  • Pembrolizumab
  • Marietta, Georgia
  • +2 more
Jan 27, 2023

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023

Leukemia, Myeloid, Acute Trial in United States (VCAR33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • VCAR33
  • La Jolla, California
  • +9 more
Aug 14, 2023

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, JNJ-64300535, ETV monohydrate)

Active, not recruiting
  • Hepatitis B, Chronic
  • Edegem, Belgium
  • +12 more
Jan 17, 2023

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Pterygium Trial in Balikesir (Expression of CD44, E-cadherin and PCNA)

Not yet recruiting
  • Pterygium
  • Expression of CD44, E-cadherin and PCNA
  • Balıkesir, Turkey
    Hümeyra Yildirim
Sep 15, 2023

Breast Cancer Trial in Beijing (99mTc-MY6349 SPECT/CT scan)

Recruiting
  • Breast Cancer
  • 99mTc-MY6349 SPECT/CT scan
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 24, 2023

Recurrent Malignant Glioma Trial in Goyang-si (YYB-103)

Recruiting
  • Recurrent Malignant Glioma
  • Goyang-si, Gyeonggi, Korea, Republic of
    National Cancer Center, Korea
Sep 12, 2022

Multiple Myeloma Trial in Beijing, Guangzhou, Shanghai (TQB2934 injection)

Not yet recruiting
  • Multiple Myeloma
  • TQB2934 injection
  • Beijing, Beijing, China
  • +2 more
Dec 8, 2022

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Relapsed/Refractory B-Cell Malignancies Trial (CD19 Chimeric Antigen Receptor (CAR) T Cells)

Not yet recruiting
  • Relapsed/Refractory B-Cell Malignancies
  • CD19 Chimeric Antigen Receptor (CAR) T Cells
  • (no location specified)
Jun 28, 2021

T Cell Lymphoma, T-cell Leukemia Trial in Beijing (chimeric antigen receptor T cell treatment)

Recruiting
  • T Cell Lymphoma
  • T-cell Leukemia
  • chimeric antigen receptor T cell treatment
  • Beijing, Beijing, China
    Beijing Boren Hospital
Aug 12, 2022

SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

Not yet recruiting
  • SLE (Systemic Lupus)
  • CAR T-cell therapy
  • Bangkok, Please Select, Thailand
    King Chulalongkorn Memorial Hospital
Nov 23, 2023

Advanced/ Metastatic Solid Tumors Trial in Shanghai (FDA018-ADC)

Recruiting
  • Advanced/ Metastatic Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 14, 2021